• Publications
  • Influence
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
TLDR
Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients and a proportional hazards model examined the effects of treatment arm and time to recurrence on survival after recurrence among patients who recurred. Expand
Intracavernous pressure responses to physical and electrical stimulation of the cavernous nerve in rats.
TLDR
Both cavernous pressure measurements and electrostimulation of cavernous nerves may aid surgeons during radical prostatectomy, and a change in cavernous Pressure is a sensitive indicator of Cavernous nerve manipulation. Expand
Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate.
TLDR
It is concluded that transurethral resection of the prostate may be held in reserve for patients who do not respond to endocrine therapy or those whoDo not wish to risk sexual impotence. Expand
Cytoreductive surgery for stage IV renal cell carcinoma.
TLDR
Since regression of extra renal lesions is the goal of systemic therapy, the data suggest that nephrectomy and most other cytoreductive operations in preparation for systemic therapy are not efficient treatment strategies. Expand
Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer.
TLDR
Intravesical BCG therapy for the treatment of muscle invasive transitional cell carcinoma of the bladder is ineffective and fibronectin expression in the bladder of patients with invasive disease is variable and does not correlate significantly with the clinical response toBCG therapy. Expand
Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy.
TLDR
Activation of the intrinsic system of coagulation may provide one link between the vascular endothelial surface alterations caused by IL-2 infusions and the development of the systemic toxicity that resembles septic shock. Expand
Urinary interleukins in patients receiving intravesical bacillus calmette‐guerin therapy for superficial bladder cancer
TLDR
The authors conclude that the presence of bioactive IL‐2 in urine is not required for the prevention of recurrent superficial bladder cancer. Expand
Interleukin-2 self-association.
TLDR
The self-association of human recombinant interleukin-2 from E. coli was explored and IL-2-mediated phospholipid vesicle fusion/aggregation was explored, with pronounced effects on the surface exposure of Trp-121 and the apparent quantum yield of TrP-121. Expand
Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
TLDR
The results support the view that initial treatment with interleukin-2 immunotherapy, followed by abdominal cytoreductive surgery if the peripheral metastases have regressed, may be preferable to the practice of performing abdominal cytoresective surgery before administering interleucin- 2 immunotherapy for patients with widely metastatic renal cell carcinoma. Expand
Effects of α-Difluoromethylornithine and Recombinant Interferon-α2 on the Growth of a Human Renal Cell Adenocarcinoma Xenograft in Nude Mice
TLDR
Combined therapy with DFMO and IFN-α2 is more effective than is single-drug therapy, and the mechanism by which these drugs coordinately inhibit tumor growth is unclear but appears to be associated with direct inhibition of tumor cell proliferation, possibly by modulation of polyamine metabolism. Expand
...
1
2
3
4
5
...